Scarica l'app Stockscreener
17.59
1.79%
0.31
Dopo l'orario di chiusura:
17.20
-0.39
-2.22%
Entrada Therapeutics Inc Borsa (TRDA) Ultime notizie
Entrada Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - Marketscreener.com
(TRDA) Proactive Strategies - Stock Traders Daily
Recent Price Trend in Entrada Therapeutics (TRDA) is Your Friend, Here's Why - MSN
XTX Topco Ltd Takes $634,000 Position in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - MarketBeat
Entrada Therapeutics, Inc. (NASDAQ:TRDA) Shares Sold by Fmr LLC - MarketBeat
Is Entrada Therapeutics, Inc.'s (NASDAQ:TRDA) Recent Stock Performance Tethered To Its Strong Fundamentals? - Simply Wall St
Entrada Therapeutics (NASDAQ:TRDA) Upgraded at Roth Capital - Defense World
Roth Mkm Begins Coverage on Entrada Therapeutics (NASDAQ:TRDA) - MarketBeat
Roth MKM starts ‘overlooked’ Entrada Therapeutics with Buy rating - Yahoo Finance
Entrada Therapeutics, Inc. (NASDAQ:TRDA) Shares Purchased by Janus Henderson Group PLC - MarketBeat
Jacobs Levy Equity Management Inc. Has $3.23 Million Stock Position in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - MarketBeat
Insider Sell Alert: Natarajan Sethuraman Sells Shares of Entrada Therapeutics Inc (TRDA) - GuruFocus.com
Entrada Therapeutics CFO sells shares worth nearly $120,000 By Investing.com - Investing.com Nigeria
Entrada Therapeutics president sells $320,619 in stock By Investing.com - Investing.com Nigeria
Entrada Therapeutics CFO sells shares worth nearly $120,000 - Investing.com India
Entrada Therapeutics president sells $320,619 in stock - Investing.com
Entrada Therapeutics stock hits 52-week high at $20.5 By Investing.com - Investing.com Canada
Massachusetts Financial Services Co. MA Invests $1.11 Million in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - MarketBeat
Entrada Therapeutics (TRDA) Is a Great Choice for 'Trend' Investors, Here's Why - MSN
(TRDA) Investment Analysis and Advice - Stock Traders Daily
Connor Clark & Lunn Investment Management Ltd. Has $2.22 Million Holdings in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - MarketBeat
Los Angeles Capital Management LLC Makes New $542,000 Investment in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - MarketBeat
Insider Sale at Entrada Therapeutics Inc (TRDA) by President of Research & Development - GuruFocus.com
500: Something went wrong - Investing.com UK
Entrada Therapeutics stock hits 52-week high at $20.28 By Investing.com - Investing.com Canada
Entrada Therapeutics, Inc. (TRDA) Reports Q3 Loss, Tops Revenue Estimates - MSN
HC Wainwright Issues Positive Forecast for Entrada Therapeutics (NASDAQ:TRDA) Stock Price - Defense World
HC Wainwright Analysts Boost Earnings Estimates for TRDA - MarketBeat
Entrada Therapeutics (NASDAQ:TRDA) Stock Price Expected to Rise, Oppenheimer Analyst Says - Defense World
Entrada Therapeutics president sells shares worth $339,280 By Investing.com - Investing.com Australia
Equities Analysts Issue Forecasts for TRDA FY2024 Earnings - MarketBeat
HC Wainwright Has Positive Outlook of TRDA FY2024 Earnings - MarketBeat
Beyond The Numbers: 4 Analysts Discuss Entrada Therapeutics Stock - Benzinga
Oppenheimer Issues Positive Forecast for Entrada Therapeutics (NASDAQ:TRDA) Stock Price - MarketBeat
Entrada Therapeutics stock target increased on positive trial data By Investing.com - Investing.com UK
Entrada Therapeutics (NASDAQ:TRDA) Price Target Raised to $20.00 - MarketBeat
Entrada Therapeutics Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Entrada Therapeutics’ Q3 2024 Financial Highlights - TipRanks
Entrada Therapeutics (NASDAQ:TRDA) Hits New 12-Month HighHere's What Happened - MarketBeat
Entrada Therapeutics stock hits 52-week high at $18.22 By Investing.com - Investing.com UK
Entrada Therapeutics : Corporate Presentation - Marketscreener.com
Entrada Therapeutics Reports Third Quarter 2024 Financial Results - The Manila Times
Here's Why Momentum in Entrada Therapeutics (TRDA) Should Keep going - MSN
Entrada Therapeutics, Inc. (NASDAQ:TRDA) Short Interest Down 19.1% in October - MarketBeat
Short Interest in Entrada Therapeutics, Inc. (NASDAQ:TRDA) Declines By 19.1% - Defense World
Here's What Could Help Entrada Therapeutics (TRDA) Maintain Its Recent Price Strength - MSN
Entrada Therapeutics president sells $10,800 in stock By Investing.com - Investing.com Australia
Natarajan Sethuraman Sells 600 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) Stock - MarketBeat
2.88%
2.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):